468 related articles for article (PubMed ID: 17333193)
1. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
Danson S; Ranson M; Denneny O; Cummings J; Ward TH
Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
3. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
4. Intra-laboratory comet assay sample scoring exercise for determination of formamidopyrimidine DNA glycosylase sites in human mononuclear blood cell DNA.
Møller P; Friis G; Christensen PH; Risom L; Plesner G; Kjaersgaard J; Vinzents P; Loft S; Jensen A; Tved M
Free Radic Res; 2004 Nov; 38(11):1207-14. PubMed ID: 15621698
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the action of the restriction endonuclease AluI using three different comet assay protocols.
Müller WU; Ciborovius J; Bauch T; Johannes C; Schunck C; Mallek U; Böcker W; Obe G; Streffer C
Strahlenther Onkol; 2004 Oct; 180(10):655-64. PubMed ID: 15480515
[TBL] [Abstract][Full Text] [Related]
6. Melphalan-induced DNA damage in p53(+/-) and wild type mice analysed by the comet assay.
Cordelli E; Cinelli S; Lascialfari A; Ranaldi R; Pacchierotti F
Mutat Res; 2004 Jun; 550(1-2):133-43. PubMed ID: 15135647
[TBL] [Abstract][Full Text] [Related]
7. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
8. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.
Hartley JM; Spanswick VJ; Gander M; Giacomini G; Whelan J; Souhami RL; Hartley JA
Clin Cancer Res; 1999 Mar; 5(3):507-12. PubMed ID: 10100700
[TBL] [Abstract][Full Text] [Related]
9. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
10. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
Dehn DL; Inayat-Hussain SH; Ross D
J Pharmacol Exp Ther; 2005 May; 313(2):771-9. PubMed ID: 15665137
[TBL] [Abstract][Full Text] [Related]
11. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds.
Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D
Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283
[TBL] [Abstract][Full Text] [Related]
12. Radiation-induced DNA damage and repair in peripheral blood mononuclear cells from Nijmegen breakage syndrome patients and carriers assessed by the Comet assay.
Bürger S; Schindler D; Fehn M; Mühl B; Mahrhofer H; Flentje M; Hoehn H; Seemanová E; Djuzenova CS
Environ Mol Mutagen; 2006 May; 47(4):260-70. PubMed ID: 16470524
[TBL] [Abstract][Full Text] [Related]
13. The sensitivity of the alkaline comet assay in detecting DNA lesions induced by X rays, gamma rays and alpha particles.
Rössler U; Hornhardt S; Seidl C; Müller-Laue E; Walsh L; Panzer W; Schmid E; Senekowitsch-Schmidtke R; Gomolka M
Radiat Prot Dosimetry; 2006; 122(1-4):154-9. PubMed ID: 17182604
[TBL] [Abstract][Full Text] [Related]
14. Performance of the comet assay in a high-throughput version.
Stang A; Witte I
Mutat Res; 2009 Apr; 675(1-2):5-10. PubMed ID: 19386240
[TBL] [Abstract][Full Text] [Related]
15. Could a strong alkali deproteinization replace the standard lysis step in alkaline single cell gel electrophoresis (comet) assay (pH>13)?
Vivek Kumar PR; Cheriyan VD; Seshadri M
Mutat Res; 2009 Aug; 678(1):65-70. PubMed ID: 19563911
[TBL] [Abstract][Full Text] [Related]
16. Variation in assessment of oxidatively damaged DNA in mononuclear blood cells by the comet assay with visual scoring.
Forchhammer L; Bräuner EV; Folkmann JK; Danielsen PH; Nielsen C; Jensen A; Loft S; Friis G; Møller P
Mutagenesis; 2008 May; 23(3):223-31. PubMed ID: 18326868
[TBL] [Abstract][Full Text] [Related]
17. Calibration of the comet assay for the measurement of DNA damage in mammalian cells.
Pitozzi V; Pallotta S; Balzi M; Bucciolini M; Becciolini A; Dolara P; Giovannelli L
Free Radic Res; 2006 Nov; 40(11):1149-54. PubMed ID: 17050168
[TBL] [Abstract][Full Text] [Related]
18. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cisplatin-DNA crosslinks formation with UV-C application by the alkaline Comet-assay.
Hovhannisyan GG; Haroutunyan TS; Arutyunyan RM
Exp Oncol; 2004 Sep; 26(3):240-2. PubMed ID: 15494695
[TBL] [Abstract][Full Text] [Related]
20. Sizing highly fragmented DNA in individual apoptotic cells using the comet assay and a DNA crosslinking agent.
Olive PL; Banáth JP
Exp Cell Res; 1995 Nov; 221(1):19-26. PubMed ID: 7589245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
